Insiders Trades

★ Sign in to follow

KP

Kyle Piskel

Responsable Comptable Principal

US·SEC (Form 4)

Adaptive Biotechnologies Corp

Insider activity · 24 months0 buys5 salesCumulative net flow

Nov 24 · 0 buys · 1 saleDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 1 saleJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 2 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 1 saleApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

32

Company

1

▲ Purchases (0 ops.)

—

▼ Sales (18 ops.)

€3.2M

Latest filing published 13 Mar 2026 for Adaptive Biotechnologies Corp, €212k.

Filing timeline

BuySale

Kyle Piskel

Insider track record

Disclosed buys

0

Disclosed sells

18

Not enough buy signals with a settled T+90 horizon to measure a track record yet.

Signal history

Kyle Piskel: trading record in brief

Kyle Piskel discloses dealings in Adaptive Biotechnologies Corp to SEC (Form 4). Over a trading history stretching from 15 November 2021 to 11 March 2026, the count stands at 32 filings.

No open-market purchase appears, only 18 sales worth €3.2M. The rest of the record consists of 8 share grants and 6 option exercises. 2026 to date brings no purchases and 3 sales.

Most recently, on 13 March 2026, the filings show an open-market sale worth €212k in Adaptive Biotechnologies Corp. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.

Companies and markets linked to Kyle Piskel

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Adaptive Biotechnologies Corp (US)

Declarations22 total

▼

Chief Financial OfficerExecutives11 Mar 2026Adaptive Biotechnologies Corp

245,910 USD49SEC

18,672 shares@ US$13.175.1% of flowCommon StockSEC:0001780662-26-000006:0

◆

Chief Financial OfficerExecutives4 Mar 2026Adaptive Biotechnologies Corp

0SEC

61,875 shares0Common StockSEC:0001780662-26-000004:0

◇

Chief Financial OfficerExecutives4 Feb 2026Adaptive Biotechnologies Corp

26,040 USD30SEC

2,145 shares@ US$12.140.5% of flowCommon StockSEC:0001780662-26-000002:0

◇

Chief Financial OfficerExecutives12 Jan 2026Adaptive Biotechnologies Corp

52,081 USD30SEC

4,290 shares@ US$12.141.1% of flowCommon StockSEC:0001780662-26-000001:0

◇

Chief Financial OfficerExecutives28 Nov 2025Adaptive Biotechnologies Corp

78,469 USD17SEC

11,980 shares@ US$6.551.8% of flowCommon StockSEC:0001780662-25-000003:0

◇

Chief Financial OfficerExecutives28 Nov 2025Adaptive Biotechnologies Corp

29,250 USD17SEC

3,750 shares@ US$7.800.7% of flowCommon StockSEC:0001780662-25-000003:1

◇

Chief Financial OfficerExecutives28 Nov 2025Adaptive Biotechnologies Corp

1M USD20SEC

94,384 shares@ US$12.1425.6% of flowCommon StockSEC:0001780662-25-000003:2

▼

Chief Financial OfficerExecutives28 Nov 2025Adaptive Biotechnologies Corp

3M USD39SEC

162,820 shares@ US$19.5070.8% of flowCommon StockSEC:0001780662-25-000003:3

▼

Chief Financial OfficerExecutives17 Nov 2025Adaptive Biotechnologies Corp

3,344 USD32SEC

238 shares@ US$14.050.1% of flowCommon StockSEC:0001780662-25-000002:0

▼

Chief Financial OfficerExecutives16 May 2025Adaptive Biotechnologies Corp

17,149 USD17SEC

1,929 shares@ US$8.890.4% of flowCommon StockSEC:0001062993-25-009904:0

◆

Chief Financial OfficerExecutives15 May 2025Adaptive Biotechnologies Corp

0SEC

7,815 shares0Common StockSEC:0001062993-25-009837:0

◇

Chief Financial OfficerExecutives14 Mar 2025Adaptive Biotechnologies Corp

15,800 USD17SEC

2,500 shares@ US$6.320.4% of flowCommon StockSEC:0001062993-25-005645:0

◆

Chief Financial OfficerExecutives4 Mar 2025Adaptive Biotechnologies Corp

0SEC

125,000 shares0Common StockSEC:0001062993-25-004813:0

▼

Chief Financial OfficerExecutives18 Nov 2024Adaptive Biotechnologies Corp

1,235 USD17SEC

248 shares@ US$4.980.0% of flowCommon StockSEC:0001062993-24-019373:0

◆

Chief Financial OfficerExecutives15 May 2024Adaptive Biotechnologies Corp

0SEC

31,260 shares0Common StockSEC:0001062993-24-010709:0

◆

Principal Accounting OfficerExecutives4 Mar 2024Adaptive Biotechnologies Corp

0SEC

43,740 shares0Common StockSEC:0001062993-24-005768:0

▼

Principal Accounting OfficerExecutives16 Nov 2023Adaptive Biotechnologies Corp

1,070 USD17SEC

259 shares@ US$4.130.0% of flowCommon StockSEC:0001062993-23-021224:0

◆

Principal Accounting OfficerExecutives6 Mar 2023Adaptive Biotechnologies Corp

0SEC

43,735 shares0Common StockSEC:0001062993-23-006330:0

▼

Principal Accounting OfficerExecutives16 Nov 2022Adaptive Biotechnologies Corp

2,723 USD29SEC

307 shares@ US$8.870.1% of flowCommon StockSEC:0001209191-22-057531:0

▼

Principal Accounting OfficerExecutives16 Nov 2022Adaptive Biotechnologies Corp

8,506 USD29SEC

959 shares@ US$8.870.2% of flowCommon StockSEC:0001209191-22-057432:0

◆

Principal Accounting OfficerExecutives4 Mar 2022Adaptive Biotechnologies Corp

0SEC

41,186 shares0Common StockSEC:0001209191-22-017396:0

◆

Principal Accounting OfficerExecutives15 Nov 2021Adaptive Biotechnologies Corp

0SEC

3,837 shares0Common StockSEC:0001209191-21-065312:0

22 of 22 declarations